A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer

Molecular Therapy

Volumn 17, Issue 2, 2009, Pages 389-394

  Fong, Yuman ^a   Kim, Teresa ^a   Bhargava, Amit ^a   Schwartz, Larry ^a   Brown, Karen ^a   Brody, Lynn ^a   Covey, Anne ^a   Karrasch, Matthias ^b   Getrajdman, George ^a   Mescheder, Axel ^b   Jarnagin, William ^a   Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; FLOXURIDINE; IRINOTECAN; NV 1020; OXALIPLATIN; FLUOROURACIL; FOLINIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MALE; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR VOLUME; COLORECTAL TUMOR; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

HERPES; SIMPLEXVIRUS;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; TREATMENT OUTCOME;

EID: 63649158265     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.240     Document Type: Article

References (36)

1. Meignier, B and Roizman, B (1989). Genetic engineering and properties of novel herpes simplex viruses for use as potential vaccines and as vectors of foreign genes. Adv Exp Med Biol 257: 187-192.
2. Roizman, B, Warren, J, Thuning, CA, Fanshaw, MS, Norrild, B and Meignier, B (1982). Application of molecular genetics to the design of live herpes simplex virus vaccines. Dev Biol Stand 52: 287-304.
3. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
4. Kemeny, N, Brown, K, Covey, A, Kim, T, Bhargava, A, Brody, LA et al. (2006). A Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214-1224.
5. Rampling, R, Cruickshank, G, Papanastassiou, V, Nicoll, J, Hadley, D, Brennan, D et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866.
6. Kwong, YL, Chen, SH, Kosai, K, Finegold, M and Woo, SL (1997). Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest 112: 1332-1337.
7. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 11: 1648-1658.
8. Meignier, B and Roizman, B (1985). Herpes simplex virus vaccines. Antiviral Res (suppl. 1): 259-65.
9. Cadoz, M, Micoud, M, Seigneurin, JM, Mallaret, MR, Baccard, C and Morand, P (1992). Phase I trial of R7020: A live attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 11 October 1992.
10. Meignier, B, Martin, B, Whitley, RJ and Roizman, B (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162: 313-321.
11. Meignier, B, Longnecker, R and Roizman, B (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158: 602-614.
12. Fong, Y, Jarnagin, WR, Guilfoyle, B, Tufaro, F, Haag, N, Glasschroeder, B et al. (2005). Results of a phase 1, dose-escalating study of the safety, tolerability, and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, NV1020, in subjects with hepatic colorectal metastases. Am Soc Clin Oncol Abstract 242.
13. Bennett, JJ, Delman, KA, Burt, BM, Mariotti, A, Malhotra, S, Zager, J et al. (2002). Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945.
14. Stanziale, SF, Stiles, BM, Bhargava, A, Kerns, SA, Kalakonda, N and Fong, Y (2004). Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther 15: 609-618.
15. Kucharczuk, JC, Randazzo, B, Chang, MY, Amin, KM, Elshami, AA, Sterman, DH et al. (1997). Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57: 466-471.
16. Stiles, B, Bhargava, A, Adusumili, P, Stanziale, SF, Kim, TH, Rusch, VW et al. (2003). The replication-competent oncolytic herpes simplex virus mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 134: 357-364.
17. Stiles, B, Adusumilli, P, Bhargava, A, Stanziale, S, Kim, T, Chan, M et al. (2006). Minimally-invasive localization of oncolytic herpes simplex viral therapy of micrometastatic pleural cancer. Cancer Gene Ther 13: 53-64.
18. Carew, JF, Kooby, DA, Halterman, MW, Federoff, HJ and Fong, Y (1999). Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytolytic herpes simplex virus type 1 (G207). Hum Gene Ther 10: 1599-1606.
19. Kooby, DA, Carew, JF, Halterman, MW, Mack, JE, Bertino, JR, Blumgart, LH et al. (1999). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 6: 499-504.
20. Delman, KA, Bennett, JJ, Zager, JS, Burt, BM, McAuliffe, PF, Petrowsky, H et al. (2000). Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 11: 2465-2472.
21. Rocklin, MS, Senagore, A and Talbott, T (1991). Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. Dis Colon Rectum 34: 794-797.
22. Wong, IH, Yeo, W, Chan, AT and Johnson, PJ (2001). Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. Cancer Lett 162: 65-73.
23. Choi, MY, Lee, KM, Chung, JK, Lee, DS, Jeong, JM, Park, JG et al. (2005). Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 19: 123-129.
24. Webb, A, Scott-Mackie, P, Cunningham, D, Norman, A, Andreyev, J, O'Brien, M et al. (1995). The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 6: 581-587.
25. Novis, BH, Gluck, E, Thomas, P, Steele, GD, Zurawski, VR Jr., Stewart, R et al. (1986). Serial levels of Ca 19-9 and CEA in colonic cancer. J Clin Oncol 4: 987.
26. Herrlinger, U, Kramm, CM, Aboody-Guterman, KS, Silver, JS, Ikeda, K, Johnston, KM et al. (1998). Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5: 809-819.
27. Nemunaitis, J, Cunningham, C, Buchanan, A, Blackburn, A, Edelman, G, Maples, P et al. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther 8: 746-759.
28. Wong, RJ, Kim, SH, Joe, JK, Shah, JP, Johnson, PA and Fong, Y (2001). Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193: 12-21.
29. Petrowsky, H, Roberts, GD, Kooby, DA, Burt, BM, Bennett, JJ, Delman, KA et al. (2001). Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 75: 7050-7058.
30. Zager, JS, Delman, KA, Malhotra, S, Ebright, MI, Bennett, JJ, Kates, T et al. (2001). Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 7: 561-568.
31. Ebright, MI, Zager, JS, Malhotra, S, Delman, KA, Weigel, TL, Rusch, VW et al. (2002). Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 124: 123-129.
32. Braun, DK, Roizman, B and Pereira, L (1984). Characterization of post-translational products of herpes simplex virus gene 35 proteins binding to the surfaces of full capsids but not empty capsids. J Virol 49: 142-153.
33. Heid, CA, Stevens, J, Livak, KJ and Williams, PM (1996). Real time quantitative PCR. Genome Res 6: 986-994.
34. Luoh, SM, Di Marco, F, Levin, N, Armanini, M, Xie, MH, Nelson, C et al. (1997). Cloning and characterization of a human leptin receptor using a biologically active leptin immunoadhesin. J Mol Endocrinol 18: 77-85.
35. Kemeny, N and Fong, Y (1997). Treatment of liver metastases. In: Holland, JF, Frei, E, Bast, RC, Kufe, DW, Morton, DL and Weichselbaum, RR (eds). Cancer Medicine, 4 edn. Williams & Wilkins: Baltimore, MD. pp. 1939-1954.
36. Kaplan, EL and Meier, P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.